Oscar Health: A Cautionary Tale of Earnings and Expectations

In a world where healthcare technology meets the mercurial markets, Oscar Health, Inc. (NYSE: OSCR) has delivered a rather sobering update on its second quarter financial results. The company announced a preliminary earnings surprise, reporting an expected loss from operations of approximately $230 million and a net loss of about $228 million for Q2 2025. If you’re keeping score at home, that’s not exactly the kind of EPS (earnings per share) headline that gets investors dancing in the streets.

What Went Wrong?

Oscar Health's dismal performance can be traced back to a thorough review of the 2025 Marketplace data, specifically the "2Q Risk Adjustment Reports" from Wakely, an independent actuarial firm. This analysis revealed that the average morbidity of the market was worse than previously estimated, prompting the company to revise its full-year guidance significantly. With a medical loss ratio now expected between 86.0% and 87.0%, one has to wonder: how does one even adjust for a medical loss ratio so high? It’s like trying to fit a square peg in a round hole.

Full-Year Guidance Under Pressure

Oscar is adjusting its full-year 2025 revenue forecast to between $12.0 billion and $12.2 billion, along with a SG&A (selling, general, and administrative) expense ratio of 17.1% to 17.6%. With a loss from operations projected between $300 million and $200 million, the adjusted EBITDA loss is anticipated to be approximately $120 million less than the loss from operations. It's a bit of a roller coaster, isn’t it? Just when you think the ride is leveling out, you hit another drop.

Market Reactions and Future Implications

While Oscar's earnings consensus was already on shaky ground, this announcement is likely to rattle investors further. The company’s CEO, Mark Bertolini, emphasized the competitive nature of the individual market but also hinted at necessary pricing actions for 2026. In other words, it seems Oscar is gearing up for a tough fight — a bit like David preparing to take on Goliath, only in this case, Goliath has a medical degree.

Oscar's woes could spell trouble not just for the company but for its peers in the healthcare sector. As the ACA Marketplace grapples with rising risk scores and elevated utilization trends, other players might also need to reassess their strategies. If Oscar is any indication, 2025 is shaping up to be a year of recalibration for the entire industry.

The Road Ahead

Looking forward, Oscar plans to resubmit rate filings for 2026, covering about 98% of its current membership. This is a move that could stabilize its financial standing, assuming it can accurately gauge the risk adjustment percentages. As they prepare for their second quarter financial results, which are slated for release on August 6, 2025, the market will be watching closely, perhaps with a mix of hope and skepticism.